Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It's Apples Versus Oranges in the PI3 Kinase Race

This article was originally published in Start Up

Executive Summary

Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.

You may also be interested in...



CMEA 8 Is Kaput, But A Would-Be Partner Moves On With Wellspring

Just this past January, CMEA was touting its upcoming eighth fund and two new partners with a string of early-stage biotech successes on their resumes. The fund is now dissolved, but one would-be CMEA 8 partner has moved on with a new asset-centric incubator.

CMEA 8 Is Kaput, But A Would-Be Partner Moves On With Wellspring

Two months ago, CMEA was touting its upcoming eighth fund and two new partners with a string of early-stage biotech successes on their resumes. The fund is now dissolved, but one would-be CMEA 8 partner has moved on with a new asset-centric incubator.

Paloma Pharmaceuticals Inc.

Paloma Pharmaceuticals Inc. is initially opting for an ophthalmology indication for its PI3K program. It plans to bring its lead compound, an allosteric inhibitor, into clinical trials for age-related macular degeneration in 2010. If all goes well, Paloma might move the same compound into a Phase I oncology trial later that year.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091863

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel